obicetrapib 10 mg + ezetimibe 10 mg FDC daily Clinical Trials
2 recruitingDrug
Phase 32
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Type 2 Diabetes (T2DM)LipidemiaMetabolic Syndrome (MetS)
NewAmsterdam Pharma300 enrolled20 locationsNCT07219602
Recruiting
Phase 3
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Coronary Artery DiseaseLipidemiaPlaque, Atherosclerotic
NewAmsterdam Pharma300 enrolled1 locationNCT06305559